Natco Pharma advances on receiving final approval from USFDA for Azacitidine for Injection

27 Jun 2017 Evaluate

Natco Pharma is currently trading at Rs. 979.70, up by 7.20 points or 0.74% from its previous closing of Rs. 972.50 on the BSE.

The scrip opened at Rs. 1009.00 and has touched a high and low of Rs. 1009.00 and Rs. 975.00 respectively. So far 6,590 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1080.00 on 09-Jun-2017 and a 52 week low of Rs. 495.00 on 09-Nov-2016.

Last one week high and low of the scrip stood at Rs. 1009.00 and Rs. 963.00 respectively. The current market cap of the company is Rs. 17,076.00 crore.

The promoters holding in the company stood at 51.24%, while Institutions and Non-Institutions held 26.70% and 22.05% respectively.

Natco Pharma has received final approval of Abbreviated New Drug Application (ANDA) from the US Food and Drug Administration (USFDA) for Azacitidine for Injection, 100mg per Vial, Single-Dose Vial, a generic version of Vidaza by Celgene Corporation.

NATCO and its marketing partner Breckenridge Pharmaceutical, Inc. (BPI) plan to launch this product in the USA market in the near future.

Vidaza is a prescription anti-cancer chemotherapy drug that is indicated to treat myelodysplastic syndrome (MDS). Vidaza generated total combined sales of $188 million for the twelve-month period ending April, 2017, based on industry sales data.


Natco Pharma Share Price

890.75 -12.80 (-1.42%)
01-Jan-2026 09:43 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1712.00
Dr. Reddys Lab 1253.30
Cipla 1501.30
Zydus Lifesciences 909.00
Lupin 2092.90
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×